NCT07760519Not yet recruiting
A Multicenter Observational PMS Study Assessing Durvalumab Safety in Indian Adults With Resectable NSCLC
A Prospective, Observational, Multicenter, Post Marketing Surveillance Study to Assess Safety of Durvalumab in Indian Adult Patients With Resectable Non-Small Cell Lung Cancer (NSCLC)
Source: ClinicalTrials.gov · Last updated 30 Oct 2026
Brief summary (registry, in English)
This will be a single-arm, multicenter, prospective, observational, real-world study and the data source is the patients' medical record at each site. A total of 78 patients will be enrolled in the study.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 78 (estimated)
- First submitted
- 17 Jun 2026
- Start date
- 30 Nov 2026
- Primary completion date
- 30 Apr 2030
- Lead sponsor
- AstraZeneca
- Diseases
- Lung cancer
- NCT number
- NCT07760519
What you commit to
- Study type: Observational
- Planned participants: 78
- From 30 Nov 2026 to the primary completion date, 30 Apr 2030
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior treatment with durvalumab for any other indications
- Requires concurrent treatment for cancers other than resectable NSCLC
- Patients with active or prior autoimmune disease or with medical conditions that required systemic corticosteroids or immunosuppressants
Other illness
- Presence of unresectable or metastatic disease.
- Any condition that, in the opinion of the investigator, would interfere with the patient's participation in the study.
Other
- Concurrently participating in any other clinical trial
Who the study is looking for
- Patients with newly diagnosed previously untreated resectable NSCLC (tumors ≥ 4 cm and/or node positive) and no known EGFR mutations or ALK rearrangements prescribed with durvalumab as per local prescriber information.
- Provision of signed, written and dated informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.